TOP TEN perturbations for 219096_at (Homo sapiens)

Organism: Homo sapiens
Gene: 219096_at
Selected probe(set): 219096_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 219096_at (219096_at) across 5961 perturbations tested by GENEVESTIGATOR:

atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)

Relative Expression (log2-ratio):1.5429621
Number of Samples:20 / 19
Experimental atopic dermatitis study 12 (non-lesional; adults)
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (non-lesional; children)
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):-1.5424442
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)

Relative Expression (log2-ratio):1.3024998
Number of Samples:20 / 18
Experimental atopic dermatitis study 12 (lesional; adults)
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (lesional; children)
Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-1.2064161
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):-1.1933002
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-1.1420469
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):-1.1339903
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):-1.1292944
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

juvenile enthesitis related arthritis study 2 (ERA) / normal PBMC sample

Relative Expression (log2-ratio):-1.1192865
Number of Samples:3 / 27
Experimental juvenile enthesitis related arthritis study 2 (ERA)
Peripheral blood mononuclear cell (PBMC) samples from children with enthesitis related arthritis (ERA).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

E. coli study 1 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):-1.1034079
Number of Samples:12 / 16
Experimental E. coli study 1
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.